Latest news with #Haifa
Al Arabiya
22 minutes ago
- Business
- Al Arabiya
Maersk halts stops in Israel's Haifa due to Iran–Israel conflict
Danish shipping giant Maersk announced Friday that it was temporarily suspending vessel calls in Israel's Haifa port due to the country's conflict with Iran. Maersk said it made the decision after 'careful analysis of threat risk reports in the context of the ongoing conflict between Israel and Iran, specifically regarding the potential risks of calling Israeli ports and the ensuing implications for the safety of our vessel crews.' 'At the moment we are not experiencing further disruptions to our scheduled operations in the region,' it added in a statement. The conflict erupted a week ago when Israel launched air strikes on Iran, saying its arch foe was on the verge of developing a nuclear weapon.
Reuters
2 hours ago
- Business
- Reuters
Shipping company Maersk temporarily pauses Haifa port calls
COPENHAGEN, June 20 (Reuters) - Container shipping company Maersk ( opens new tab said on Friday it had temporarily paused vessel calls at Israel's Haifa port amid regional tensions. The Danish company said it did not experience any further disruptions to its scheduled operations in the region. Israel has been hitting Iran from the air since last Friday in what it describes as an effort to prevent Tehran from developing nuclear weapons. Iran has denied plans to develop such weapons and has retaliated by launching counterstrikes on Israel. On Thursday, Iran's Revolutionary Guards said it had launched combined missile and drone attacks at military and industrial sites linked to Israel's defence industry in Haifa and Tel Aviv.
Yahoo
4 hours ago
- Business
- Yahoo
NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update
TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ('NurExone' or the 'Company'), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub ('HTH') Accelerator Program. Based in Boston, Massachusetts, home to more than 1,000 biotech companies1, HTH is operated by the Advanced Regenerative Manufacturing Institute ('ARMI') and its BioFabUSA initiative. NurExone's acceptance into the prestigious HTH Accelerator Program will support the Company's expansion into the U.S. market following the establishment of Exo-top Inc. ('Exo-TOP'), the Company's wholly owned U.S. subsidiary dedicated to GMP-compliant exosome manufacturing for clinical development and commercial scale-up. HTH, co-led by ARMI and Mass General Brigham, is a competitive accelerator program supported by the U.S. Department of Health and Human Services and Israel's Ministry of Health. The HTH Accelerator Program selects a limited number of innovative companies each year to help them validate U.S. clinical relevance, strengthen commercialization strategies, and build meaningful collaborations with key stakeholders across the U.S. HealthTech landscape. The program is funded by HTH at no cost to participants. Dr. Lior Shaltiel, CEO of NurExone, commented: 'The HTH Acceleration Program offers the kind of U.S.-based insight and guidance needed at this stage of our growth. As we establish Exo-TOP to manufacture clinical-grade exosomes in the U.S., the HTH will help us sharpen our regulatory and scale-up strategies and pursue meaningful commercial collaboration opportunities. This is a timely and strategic opportunity to accelerate our commercialization pathway in the world's largest healthcare market 2.' NurExone's participation in the HTH Accelerator Program is expected to enhance its visibility within the U.S. regenerative medicine ecosystem and to support its mission to bring novel exosome-based therapeutics to patients with unmet needs. Omnibus Plan Approval The Company is pleased to announce that, further to its press release dated June 4, 2025, at the Company's annual general and special meeting held on June 18, 2025 (the 'Meeting'), disinterested shareholders ratified and approved the amended and restated omnibus incentive plan (the 'Omnibus Plan'), a copy of which is available under the Company's SEDAR+ profile at The Omnibus Plan is a hybrid plan that provides flexibility to grant-equity incentive awards in the form of stock options ('Options'), restricted shares ('Restricted Shares') and restricted share units ('RSUs'). The Omnibus Plan is a hybrid 10% rolling and 10% fixed share-based compensation plan that amends and restates the Company's previous equity incentive plan approved by shareholders on June 4, 2024 (the 'Previous Plan'). The Previous Plan was a 20% fixed share-based compensation plan whereby the maximum number of common shares in the capital of the Company ('Common Shares') reserved for issuance was set at 13,166,085, representing 20% of the issued and outstanding Common Shares as of the effective date. The Omnibus Plan now includes (i) a 10% 'rolling' Option component that shall not exceed 10% of the Company's total issued and outstanding Common Shares from time to time; and (ii) a 10% fixed component permitting up to 7,800,781 RSUs and Restricted Shares in the aggregate. Additionally, the Omnibus Plan was amended to increase the number of securities issuable to insiders of the Company. The Previous Plan provided, that unless approved by disinterested shareholders, (i) the maximum number of securities issuable to insiders collectively would not exceed 10% of the Company's securities at any time and (ii) the maximum number of securities issuable to insiders collectively in any twelve-month period would not exceed 10% of the Company's total issued and outstanding securities as at the date any award was granted to an insider. Now, the Omnibus Plan provides the following that (i) the maximum number of the Company's securities issuable to insiders collectively shall not exceed 20% of the Company's total issued and outstanding Common Shares at any point in time and (ii) the maximum number of the Company's securities issuable to insiders collectively, in any 12-month period, when combined with all of the Company's other share compensation arrangements, shall not exceed 20% of the Company's total issued and outstanding securities, calculated as at the date any award is granted or issued to any insider. RSU Grants In addition, the Company announced that it has granted an aggregate of 1,125,000 RSUs to certain officers and directors of the Company pursuant to the terms and conditions of the Omnibus Plan. Each RSU vests on the one-year anniversary of the grant date and may be settled, upon their vesting, into one Common Share. The RSUs and underlying Common Shares are subject to the Exchange Hold Period (as such term is defined under the policies of the TSX Venture Exchange ('TSXV')). About NurExone NurExone Biologic Inc. is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsi. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy. For additional information and a brief interview, please watch Who is NurExone?, visit or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior ShaltielChief Executive Officer and DirectorPhone: +972-52-4803034Email: info@ Dr. Eva ReuterInvestor Relations – GermanyPhone: +49-69-1532-5857Email: Allele Capital PartnersInvestor Relations – +1 978-857-5075Email: aeriksen@ press release contains certain 'forward-looking statements' that reflect the Company's current expectations and projections about its future results. Wherever possible, words such as 'may', 'will', 'should', 'could', 'expect', 'plan', 'intend', 'anticipate', 'believe', 'estimate', 'predict' or 'potential' or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the; the Company's acceptance into the prestigious HTH Accelerator Program will support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program is expected to enhance its visibility within the U.S. regenerative medicine ecosystem and support its mission as discussed herein; each RSU will be settled into one Common Share; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company's acceptance into the prestigious HTH Accelerator Program will allow it to support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program will give the Company the ability to enhance its visibility within the U.S. regenerative medicine ecosystem and support its mission as discussed herein; each RSU will be settled into one Common Share; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company's early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; dependence on the Company's strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the inability to obtain adequate financing; the inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company's intellectual property and technology won't have the intended impact on the Company and/or its business; the Company's inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the inability of the Company to realize on the benefits of exosomes; the inability of the Company to produce and/or supply exosomes for a wide range of applications; the inability of the Company's products to be used for patient treatment; there not being broader adoption in the field and/or cell therapy applications; the inability of the Company to fulfill its intended future plans and expectations; there not being growing clinical demand for innovative treatments in spinal cord, optic nerve, and/or other therapeutic areas; the Company's inability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company's inability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine and/or cell therapy applications; the Company's inability to expand into further studies; the Company will not receive all required regulatory approvals; the Company will not have clinical and/or commercial breakthroughs in regenerative medicine; the Company will be unable to enhance its presence in key markets; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; the Company will not realize its future development plans, operational initiatives, and strategic objectives; the Company will not advance its therapeutic programs and clinical milestones; the Company will not engage with regulatory agencies; the Company's acceptance into the prestigious HTH Accelerator Program will not support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program will not enhance its visibility within the U.S. regenerative medicine ecosystem and will not support its mission as discussed herein; each RSU will not be settled into one Common Share; and the risks discussed under the heading 'Risk Factors' on pages 44 to 51 of the Company's Annual Information Form dated August 27, 2024, a copy of which is available under the Company's SEDAR+ profile at These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. i Spinal cord injury, Glaucoma 1
The Standard
5 hours ago
- The Standard
China will assist citizens in Israel to evacuate to Egypt from Friday
People take cover inside a cable car tunnel following a missile attack from Iran on Israel, at Haifa, Israel June 17, 2025. (Reuters)
Yahoo
6 hours ago
- Politics
- Yahoo
Escalate to de-escalate? What options does Iran have to end Israel war?
Iran has no clear off-ramps to end its war with Israel, which could soon drag in the United States and lead to a new quagmire in the Middle East, analysts told Al Jazeera. Since June 13, Israel has killed at least 240 Iranians, many of them civilians. Top Iranian military leaders and nuclear scientists have been among the dead. Israel has struck Iran's state television station, hit a hospital, targeted apartment blocks, and damaged the country's air defences. In response, Iran has fired barrages of ballistic missiles at Israel, targeting military and security installations, and hitting the Haifa oil refinery, residential buildings, and a hospital. At least 24 people have been killed in Israel as a result of the attacks. Israel aims to destroy Iran's nuclear programme and potentially go as far as bringing about regime change, analysts say. These goals make it difficult for Iran to navigate a quick end to the conflict. Iran's official position is that it will not negotiate while under attack, fearing it will be forced to fully surrender to US and Israeli terms. Iran may instead have to hope that US President Donald Trump can be persuaded to rein in Israel, which may be in his interest to avoid getting entangled in a far-away war, even if the US leader has recently appeared to favour striking Iran, and has reiterated that Iran cannot be allowed to have a nuclear weapon. 'If the United States recognises the urgency of de-escalation and manages to persuade Israel to halt its military campaign, then – given the mounting costs of war for Iran and the fact that Iran's primary goal is to stop, not expand, the conflict – it is highly likely that Iran would agree to a ceasefire or political resolution,' said Hamidreza Aziz, an expert on Iran for the Middle East Council for Global Affairs think theory, Iran could return to the negotiating table and sign a deal while under fire. However, Iran would be forced to entirely give up its nuclear programme, enabling its enemies to then aggressively pursue regime change without fear of consequence, analysts previously told Al Jazeera. This is an unlikely scenario, according to Reza H Akbari, an analyst on Iran and the Middle East, North Africa and South Asia Program Manager at the Institute for War and Peace Reporting. '[Iran's nuclear] program continues to remain a leverage for Iran, which enables them to even engage with the US. Giving it up would be a shocking development which I don't foresee for the time being,' he told Al Jazeera. The US and Iran had already engaged in five rounds of negotiations before Israel instigated the conflict. The two sides had reached an impasse when Trump demanded that Iran give up its entire nuclear programme, which every country has an 'inalienable right' to use for peaceful purposes, according to the Treaty on the Non-Proliferation of Nuclear Weapons, which Iran is a signatory to. Trump has since warned Iran to quickly surrender to a deal or face even more dire repercussions, hinting at regime change. Iran has few good options, said Negar Mortazavi, an expert on Iran with the Center for International Policy (CIP). She believes Iran has little to lose by retaliating against Israel, but also notes that the strategy would not necessarily give Tehran a way out of the conflict. 'If Iran does not retaliate after each attack, [Iranian officials] think [the Israeli attacks] will get harder and I think they're correct,' Mortazavi told Al Jazeera. 'But every time [Iran] retaliates, they give Israel the excuse to attack them again.'Over the last year, Iran's regional influence has suffered major setbacks, leaving it geopolitically vulnerable. Iran had long relied on its ally, the Lebanese armed group Hezbollah, to provide deterrence from direct Israeli attacks, but Hezbollah was significantly weakened after fighting an all-out war against Israel last year. In addition, Iran lost another ally when Syria's former President Bashar al-Assad was toppled in December 2024. Iran could still direct attacks against US bases and personnel through a web of Iranian-backed armed groups in the region, particularly in Iraq, said Barbara Slavin, an expert on Iran and a distinguished fellow at the Stimson Centre think tank. She believes Iranian-backed groups in Iraq could fire 'warning shots' to try and exploit US public opinion. Trump's nationalist 'America First' base remains staunchly opposed to any US involvement in wars abroad, which they view as unrelated to their domestic concerns. And anti-interventionist sentiments are likely to increase if US troops are put in harm's way as a result of any attacks related to the conflict with Iran. 'The thought of Americans dying in this would make it even more controversial for [the US] than it already is,' Slavin told Al Jazeera. Iran could also make Americans feel the impact of the war economically. It has threatened to attack commercial ships in the Strait of Hormuz, which would affect global trade and increase oil prices. But Slavin said this move would badly hurt Iran's economy, too. Slavin added that Iran also relies on commercial shipping in the Strait of Hormuz, which lies between Iran and Oman and is one of the most important shipping routes in the world, to export oil. Instead, Slavin said that Iran's best option was to contain the war with Israel and wait out the conflict, arguing that any manoeuvre to escalate against US personnel, even as a warning, is a risky gambit. Trump's administration, which includes many war hawks, has explicitly warned Iran against targeting its assets or soldiers. Iran is also wary of giving the US any easy pretext to directly enter the war on behalf of Israel, Akbari said. 'Iran's leadership knows that drawing the US further into the war could be catastrophic for both the regime and in terms of industrial damage. [It would risk destroying] everything Iran has built over the last 40-plus years,' Akbari formal position is to inflict significant political, military and material cost on Israel for instigating the war. This position was echoed by Hassan Ahmadian, an assistant professor at Tehran University, who suggested Israel's Prime Minister Benjamin Netanyahu may stop the war if Israelis feel the impact of a crisis he instigated. 'Iranians are quite confident that they can inflict enough retaliatory pain to make Israel stop [its attacks],' Ahmadian told Al Jazeera. It is unclear how much damage Iran is doing to Israel's military infrastructure since the latter bars the media from reporting such information. Furthermore, it's hard to assess how long Iran can sustain a war against Israel. But Israel itself may struggle to attack for a protracted period without the US, said Slavin. She referenced media reports that Israel is running low on defensive interceptors, which could make it more vulnerable to long-range strikes by Iran. The challenges facing both foes could prompt them to end the fighting sooner rather than later – at least that appears to be what Iran is betting on. 'Right now, Iran is trying to hunker down and somehow get through this,' Slavin said. 'No outside power will save Iran. It's up to them [to save themselves],' she told Al Jazeera.
